scholarly journals Lymphatic circulation and heart failure

2021 ◽  
Vol 23 (3) ◽  
pp. 186-191
Author(s):  
G. P. Itkin ◽  
M. G. Itkin
Keyword(s):  
Heart Failure ◽  
Current Knowledge ◽  
Fundamental Question ◽  
Interstitial Tissue ◽  
Formation Processes ◽  
Lymphatic Circulation ◽  
Cardiovascular Systems

Objective: to summarize current knowledge about the interactions between the lymphatic/cardiovascular systems and interstitial tissue, which are associated with heart failure (HF). The authors attempt to answer the fundamental question of whether lymphatic insufficiency is a cause or consequence of HF. Understanding lymph formation processes in HF will allow finding new ways of treating HF.

scholarly journals Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training

2017 ◽  
Vol 2017 ◽  
pp. 1-17 ◽  
Author(s):  
Andreas B. Gevaert ◽  
Katrien Lemmens ◽  
Christiaan J. Vrints ◽  
Emeline M. Van Craenenbroeck
Keyword(s):  
Heart Failure ◽  
Endothelial Dysfunction ◽  
Exercise Training ◽  
Ejection Fraction ◽  
Current Knowledge ◽  
Beta Blockers ◽  
Preserved Ejection Fraction ◽  
Cellular Mechanisms ◽  
Converting Enzyme Inhibitors ◽  
Reduced Ejection Fraction

Although the burden of heart failure with preserved ejection fraction (HFpEF) is increasing, there is no therapy available that improves prognosis. Clinical trials using beta blockers and angiotensin converting enzyme inhibitors, cardiac-targeting drugs that reduce mortality in heart failure with reduced ejection fraction (HFrEF), have had disappointing results in HFpEF patients. A new “whole-systems” approach has been proposed for designing future HFpEF therapies, moving focus from the cardiomyocyte to the endothelium. Indeed, dysfunction of endothelial cells throughout the entire cardiovascular system is suggested as a central mechanism in HFpEF pathophysiology. The objective of this review is to provide an overview of current knowledge regarding endothelial dysfunction in HFpEF. We discuss the molecular and cellular mechanisms leading to endothelial dysfunction and the extent, presence, and prognostic importance of clinical endothelial dysfunction in different vascular beds. We also consider implications towards exercise training, a promising therapy targeting system-wide endothelial dysfunction in HFpEF.

Respiratory and cardiovascular systems

2021 ◽  
pp. 373-496
Keyword(s):  
Heart Failure ◽  
Thoracic Cavity ◽  
Gaseous Exchange ◽  
Skeletal Tissue ◽  
Pulmonary System ◽  
Regulation Of Breathing ◽  
Lower Airways ◽  
Cardiovascular Systems ◽  
Respiratory Conditions ◽  
Ventilation And Perfusion

‘Respiratory and cardiovascular systems’ begins with the anatomy of the thoracic cavity, including the lungs, skeletal tissue, and soft tissue, before consideration of the two main physiological components of the thorax: the pulmonary and cardiovascular systems. The main structures of the pulmonary system are discussed (pleura and pleural cavities, the upper and lower airways), together with respiratory mechanics, the principles of gaseous exchange and gas transport in the blood, the relationships between ventilation and perfusion, and the regulation of breathing. Major respiratory conditions and diseases are also covered, such as cystic fibrosis, pulmonary embolism, asthma, and the effect of altitude. The cardiovascular system topics includes blood physiology (haematology and haemostasis) and the heart in terms of anatomy, its function as a pump, and the nature of the heart as an electrical tissue (the electrocardiogram). The function of the heart is discussed, including during exercise and in diseases such as heart failure and hypertension.

scholarly journals Oxidative Stress, Kinase Activity and Inflammatory Implications in Right Ventricular Hypertrophy and Heart Failure under Hypobaric Hypoxia

2020 ◽  
Vol 21 (17) ◽  
pp. 6421
Author(s):  
Eduardo Pena ◽  
Julio Brito ◽  
Samia El Alam ◽  
Patricia Siques
Keyword(s):  
Oxidative Stress ◽  
Heart Failure ◽  
Right Ventricular ◽  
Hypobaric Hypoxia ◽  
Ventricular Hypertrophy ◽  
Current Knowledge ◽  
Right Heart Failure ◽  
Right Ventricular Hypertrophy ◽  
Therapeutic Approaches ◽  
Inflammatory Molecules

High altitude (hypobaric hypoxia) triggers several mechanisms to compensate for the decrease in oxygen bioavailability. One of them is pulmonary artery vasoconstriction and its subsequent pulmonary arterial remodeling. These changes can lead to pulmonary hypertension and the development of right ventricular hypertrophy (RVH), right heart failure (RHF) and, ultimately to death. The aim of this review is to describe the most recent molecular pathways involved in the above conditions under this type of hypobaric hypoxia, including oxidative stress, inflammation, protein kinases activation and fibrosis, and the current therapeutic approaches for these conditions. This review also includes the current knowledge of long-term chronic intermittent hypobaric hypoxia. Furthermore, this review highlights the signaling pathways related to oxidative stress (Nox-derived O2.- and H2O2), protein kinase (ERK5, p38α and PKCα) activation, inflammatory molecules (IL-1β, IL-6, TNF-α and NF-kB) and hypoxia condition (HIF-1α). On the other hand, recent therapeutic approaches have focused on abolishing hypoxia-induced RVH and RHF via attenuation of oxidative stress and inflammatory (IL-1β, MCP-1, SDF-1 and CXCR-4) pathways through phytotherapy and pharmacological trials. Nevertheless, further studies are necessary.

scholarly journals Muscle Wasting and Sarcopenia in Heart Failure—The Current State of Science

2020 ◽  
Vol 21 (18) ◽  
pp. 6549
Author(s):  
Alessia Lena ◽  
Markus S. Anker ◽  
Jochen Springer
Keyword(s):  
Heart Failure ◽  
Skeletal Muscle ◽  
Chronic Heart Failure ◽  
Muscle Wasting ◽  
Current Knowledge ◽  
Strong Predictor ◽  
Ongoing Research ◽  
Cardiac Cachexia ◽  
Current State ◽  
Receptor Modulators

Sarcopenia is primarily characterized by skeletal muscle disturbances such as loss of muscle mass, quality, strength, and physical performance. It is commonly seen in elderly patients with chronic diseases. The prevalence of sarcopenia in chronic heart failure (HF) patients amounts to up to 20% and may progress into cardiac cachexia. Muscle wasting is a strong predictor of frailty and reduced survival in HF patients. Despite many different techniques and clinical tests, there is still no broadly available gold standard for the diagnosis of sarcopenia. Resistance exercise and nutritional supplementation represent the currently most used strategies against wasting disorders. Ongoing research is investigating skeletal muscle mitochondrial dysfunction as a new possible target for pharmacological compounds. Novel agents such as synthetic ghrelin and selective androgen receptor modulators (SARMs) seem promising in counteracting muscle abnormalities but their effectiveness in HF patients has not been assessed yet. In the last decades, many advances have been accomplished but sarcopenia remains an underdiagnosed pathology and more efforts are needed to find an efficacious therapeutic plan. The purpose of this review is to illustrate the current knowledge in terms of pathogenesis, diagnosis, and treatment of sarcopenia in order to provide a better understanding of wasting disorders occurring in chronic heart failure.

scholarly journals Myocardial infarction remodeling that progresses to heart failure: a signaling misunderstanding

2018 ◽  
Vol 315 (1) ◽  
pp. H71-H79 ◽  
Author(s):  
Alan J. Mouton ◽  
Osvaldo J. Rivera ◽  
Merry L. Lindsey
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Wound Healing ◽  
Current Knowledge ◽  
Healing Process ◽  
Cell Types ◽  
Left Ventricular ◽  
Wound Healing Process ◽  
The Status ◽  
The Right

After myocardial infarction, remodeling of the left ventricle involves a wound-healing orchestra involving a variety of cell types. In order for wound healing to be optimal, appropriate communication must occur; these cells all need to come in at the right time, be activated at the right time in the right amount, and know when to exit at the right time. When this occurs, a new homeostasis is obtained within the infarct, such that infarct scar size and quality are sufficient to maintain left ventricular size and shape. The ideal scenario does not always occur in reality. Often, miscommunication can occur between infarct and remote spaces, across the temporal wound-healing spectrum, and across organs. When miscommunication occurs, adverse remodeling can progress to heart failure. This review discusses current knowledge gaps and recent development of the roles of inflammation and the extracellular matrix in myocardial infarction remodeling. In particular, the macrophage is one cell type that provides direct and indirect regulation of both the inflammatory and scar-forming responses. We summarize current research efforts focused on identifying biomarker indicators that reflect the status of each component of the wound-healing process to better predict outcomes.

scholarly journals Ultrafiltration in acute heart failure: Current knowledge and fields for further research

2021 ◽  
Vol 30 (7) ◽  
pp. 0-0
Author(s):  
Szymon Urban ◽  
Mikolaj Blaziak ◽  
Jan Biegus ◽  
Robert Zymlinski
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Current Knowledge

scholarly journals Understanding Iron Deficiency in Heart Failure: Clinical Significance and Management

2018 ◽  
Vol 12 (2) ◽  
pp. 110
Author(s):  
Rajalakshmi Santhanakrishnan ◽  
Keyword(s):  
Heart Failure ◽  
New York ◽  
Iron Deficiency ◽  
Treatment Guidelines ◽  
Current Knowledge ◽  
Heart Association ◽  
Functional Class ◽  
Iron Therapy ◽  
Co Morbidity ◽  
Iv Iron

Iron deficiency (ID) has been increasingly recognized as an important co-morbidity associated with heart failure (HF). ID significantly impairs exercise tolerance and is an independent predictor of poor outcomes in people with HF irrespective of their anemic status. Diagnosis of ID in people with HF is often missed and therefore routine screening for ID is necessary for these patients. IV iron repletion has been recommended in HF treatment guidelines to improve symptoms and exercise capacity. People with ID and HF who are treated with IV iron have an improved quality of life, better 6-minute walk test results and New York Heart Association functional class. The effect of iron therapy on re-hospitalization and mortality rates in people with HF remains unclear. Large-dose oral iron treatment has been found to be ineffective in improving symptoms in people with HF. This review summarizes the current knowledge on prevalence, clinical relevance, and the molecular mechanism of ID in patients with chronic HF and the available evidence for the use of parenteral iron therapy.

scholarly journals MicroRNAs as monitoring markers for right-sided heart failure and congestive hepatopathy

2021 ◽  
Vol 14 (2) ◽  
pp. 142-147
Author(s):  
Ruxandra Florentina Ionescu ◽  
◽  
Sanda Maria Cretoiu ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Diseases ◽  
Current Knowledge ◽  
Mechanisms Of Action ◽  
Transcriptional Level ◽  
Accurate Assessment ◽  
Regulate Gene Expression ◽  
Non Coding Rnas ◽  
Post Transcriptional Regulation ◽  
Congestive Hepatopathy

The last decades showed a worrying increase in the evolution of cardiovascular diseases towards different stages of heart failure (HF), as a stigma of the western lifestyle. MicroRNAs (miRNAs), non-coding RNAs, which are approximately 22-nucleotide long, were shown to regulate gene expression at the post-transcriptional level and play a role in the pathogenesis and progression of HF. miRNAs research is of high interest nowadays, as these molecules display mechanisms of action that can influence the course of evolution of common chronic diseases, including HF. The potential of post-transcriptional regulation by miRNAs concerning the diagnosis, management, and therapy for HF represents a new promising approach in the accurate assessment of cardiovascular diseases. This review aims to assess the current knowledge of miRNAs in cardiovascular diseases, especially right-sided heart failure and hepatomegaly. Moreover, attention is focused on their role as potential molecular biomarkers and more promising aspects involving miRNAs as future therapeutic targets in the pathophysiology of HF.

Autophagy in health and disease: focus on the cardiovascular system

2017 ◽  
Vol 61 (6) ◽  
pp. 721-732 ◽  
Author(s):  
Jeanne Mialet-Perez ◽  
Cécile Vindis
Keyword(s):  
Heart Failure ◽  
Cardiovascular System ◽  
Crucial Role ◽  
Current Knowledge ◽  
Cardiovascular Disorders ◽  
Health And Disease ◽  
And Function ◽  
Autophagy Activity ◽  
Disease Focus

Autophagy is a highly conserved mechanism of lysosome-mediated protein and organelle degradation that plays a crucial role in maintaining cellular homeostasis. In the last few years, specific functions for autophagy have been identified in many tissues and organs. In the cardiovascular system, autophagy appears to be essential to heart and vessel homeostasis and function; however defective or excessive autophagy activity seems to contribute to major cardiovascular disorders including heart failure (HF) or atherosclerosis. Here, we review the current knowledge on the role of cardiovascular autophagy in physiological and pathophysiological conditions.

Sign in / Sign up

Export Citation Format

Share Document